Adagio Medical Study on Persistent Atrial Fibrillation Shows early punctual cryoablation compared to Ablation instruments, which require two procedures, superior Results obtained

Laguna Hills, California (PRNewswire / -) – Adagio Medical, Inc., developer of iCLAS (TM) technology, an intelligent low-temperature continuous lesion ablation system for the treatment of cardiac arrhythmias, provides up-to-date data on the ongoing cryoablation study for the treatment of persistent atrial fibrillation) known. The study is currently conducted in two clinical centers in Europe; Two more sites should be added early in 2019.

Until now, 25 patients have been treated with persistent and permanent atrial fibrillation. The treatment gives the PE the opportunity to create lesions to isolate the pulmonary veins, the posterior wall of the left atrium of the heart and the cavotricuspid isthmus. The Adagio AF cryoablation catheter uses preformed stylets that allow the physician to adapt the size and shape of linear lesions to the patient's specific cardiac anatomy without requiring multiple catheter changes. The catheter cooling elements are adjusted via the iCLAS cryoablation console and can reach temperatures up to -190 ° C. The ability of catheters to adapt to the anatomy of the catheter. A patient and the power of the iCLAS console are key elements in the process of isolating critical areas of targeted transmural injury.

Early follow-up data showed that after 90% of patients had no symptoms of AF, six months after a single procedure. In addition, the nine- and twelve-month data show significantly better results compared to the current industry standard, in terms of the absence of AF symptoms.

"Adagio's technology for effectively isolating the pulmonary veins and the left atrial wall is impressive, and recognizing that a single treatment is more effective than having two ablations with another device is an added benefit." ", says Professor Lucas Boersma, Chief Medical Officer at St. Anthony's Hospital in Nieuwegein, the Netherlands. "The data up to now are very promising."

"A dedicated team of technicians and scientists, led by technical director Alex Babkin, has developed a cryoablation system capable of transforming the methods of electrophysiologists to support this demanding patient population," said Hakon Bergheim, Director of Operations at Adagio Medical. "Our vision is to give the EP the power to successfully deliver a continuous transmural injury throughout the heart with a single catheter, and the success of these ongoing European studies is very encouraging." We hope to be able to count on a United States beginning of 2019. To start a study. "

About Adagio Medical

Adagio Medical, Inc. (www.adagiomedical.com) is a privately held company based in Laguna Hills, California. The company is developing innovative cryoablation technologies for continuous, linear and transmural injury training for the treatment of cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation, atrial flutter and ventricular tachycardia. Adagio Medical, Inc. is a portfolio company of Fjord Ventures. If you want more information, please contact us at the e-mail address info@adagiomedical.com.